Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00174239
Registration number
NCT00174239
Ethics application status
Date submitted
9/09/2005
Date registered
15/09/2005
Date last updated
25/05/2007
Titles & IDs
Public title
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Query!
Scientific title
A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.
Query!
Secondary ID [1]
0
0
A7231001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Parkinson Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Parkinson's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
PDSS, UPDRS
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
CGI, PGI, Epworth Sleepiness Scale, PDQ-39
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
* Idiopathic Parkinson Disease
* Must be experiencing sleep akinesia
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Current treatment with other dopamine agonists
* Nocturnal hallucinations
* Dementia
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Westmead
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
- Westmead
Query!
Recruitment postcode(s) [2]
0
0
- Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
Italy
Query!
State/province [1]
0
0
IS
Query!
Country [2]
0
0
Italy
Query!
State/province [2]
0
0
Ragusa
Query!
Country [3]
0
0
Italy
Query!
State/province [3]
0
0
Bologna
Query!
Country [4]
0
0
Italy
Query!
State/province [4]
0
0
Bolzano
Query!
Country [5]
0
0
Italy
Query!
State/province [5]
0
0
Napoli
Query!
Country [6]
0
0
Italy
Query!
State/province [6]
0
0
Padova
Query!
Country [7]
0
0
Italy
Query!
State/province [7]
0
0
Palermo
Query!
Country [8]
0
0
Italy
Query!
State/province [8]
0
0
Roma
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Asturias
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Barcelona
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Madrid
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Sevilla
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00174239
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00174239
Download to PDF